SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Laboratories gains on entering into definitive agreement with Citius Pharmaceuticals

06 Sep 2021 Evaluate

Dr. Reddy’s Laboratories is currently trading at Rs. 4923.60, up by 24.15 points or 0.49% from its previous closing of Rs. 4899.45 on the BSE.

The scrip opened at Rs. 4930.00 and has touched a high and low of Rs. 4944.45 and Rs. 4871.10 respectively. So far 0.56 lakh shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5,613.65 on 07-Jul-2021 and a 52 week low of Rs. 4,135.90 on 19-Mar-2021.

Last one week high and low of the scrip stood at Rs. 4944.45 and Rs. 4576.75 respectively. The current market cap of the company is Rs. 81,971.96 crore.

The promoters holding in the company stood at 26.73%, while Institutions and Non-Institutions held 44.78% and 28.49% respectively.

Dr. Reddy's Laboratories has entered into a definitive agreement with Citius Pharmaceuticals, Inc. (Citius) pursuant to which it sold all of its rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) and certain related assets.

Under the terms of agreement, Dr. Reddy's will receive $40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 million related to the CTCL (cutaneous T-cell lymphoma) indication approval and up to $70 million for additional indication approvals. Further, Dr. Reddy's will receive certain sales-based milestones and tiered earn-out payments.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1295.00 1.75 (0.14%)
11-May-2026 13:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.20
Dr. Reddys Lab 1295.00
Cipla 1322.70
Zydus Lifesciences 948.00
Lupin 2278.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×